 |
 |

Quantifying Skin Disease Burden in Mycosis FungoidesType Cutaneous T-Cell Lymphomas
The Severity-Weighted Assessment Tool (SWAT)
Seth R. Stevens, MD;
Malcolm S. Ke, MD;
Eileen J. Parry, MD;
Julie Mark, MD;
Kevin D. Cooper, MD
Arch Dermatol. 2002;138:42-48.
Objective To develop a quantitative tool to assess severity of mycosis fungoides.
Design Prospective analysis of a cohort.
Setting University department of dermatologybased cutaneous lymphoma
clinic.
Patients From 1984 to 1995, 1186 visits from 323 referred patients seen in a
multidisciplinary cutaneous lymphoma program.
Main Outcome Measures Severity-weighted assessment tool (SWAT) scores were obtained for patients
at each visit. This score represents the product of the percentage total body
surface area (%TBSA) involvement of each lesion type (patch, plaque, and tumor
or ulceration), multiplied by a weighting factor: SWAT = (patch %TBSA x
1) + (plaque %TBSA x 2) + (tumor or ulcer %TBSA x 3). In addition,
the standard measurements of TBSA involvement and physician global assessments
were recorded for comparison.
Results The SWAT score correlated well with %TBSA (r
= 0.95, P<.001), physician global assessment (r = 0.60, P<.001), and time
to complete remission during psoralenUV-A therapy (r = 0.80, P<.001), therefore indicating
validity against standard measures. Analysis of individual and subsets of
patients demonstrated that the SWAT score more accurately quantified changes
in skin disease burden, including mixed responses to treatment, than did %TBSA
alone.
Conclusions The SWAT score is a useful clinical measurement for mycosis fungoides.
The SWAT score captures overall physician impressions of disease status on
a continuous dimensionless numerical scale, therefore providing a defined,
objective, and sensitive quantitative measure. This tool is suitable for individual
patient assessment, clinical trials, and outcome comparisons.
From the Departments of Dermatology, University Hospitals of Cleveland,
Case Western Reserve University (Drs Stevens, Ke, Parry, Mark, and Cooper),
and Veterans Affairs Medical Center (Drs Stevens and Cooper), Cleveland, Ohio;
University of Michigan, Ann Arbor (Drs Stevens and Cooper); and Salford Royal
Hospitals National Health Service Trust, Manchester, England (Dr Parry).
CiteULike Connotea Del.icio.us Digg Reddit Technorati
What's this?
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2002;138(1):139.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Prognostic Value of Blood Eosinophilia in Primary Cutaneous T-Cell Lymphomas
Tancrede-Bohin et al.
Arch Dermatol 2004;140:1057-1061.
ABSTRACT
| FULL TEXT
Circulating CD4+CD7- Lymphocyte Burden and Rapidity of Response: Predictors of Outcome in the Treatment of Sezary Syndrome and Erythrodermic Mycosis Fungoides With Extracorporeal Photopheresis
Stevens et al.
Arch Dermatol 2002;138:1347-1350.
ABSTRACT
| FULL TEXT
|